Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 435 M
EBIT 2017 13,8 M
Net income 2017 -25,1 M
Finance 2017 420 M
Yield 2017 -
Sales 2018 480 M
EBIT 2018 10,4 M
Net income 2018 -18,3 M
Finance 2018 257 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 1 489,28
EV / Sales2017 17,3x
EV / Sales2018 16,0x
Capitalization 7 945 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology.It operates its business through the Ionis Core and Akcea Therapeutics segments.The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline... 
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
10/18 IONIS PHARMACEUTICALS : Enters into Collaboration with Seventh Sense Biosystems ..
10/18 IONIS PHARMACEUTICALS : Presents New Data from NEURO TTR Study and Highlights Pr..
10/18 AKCEA THERAPEUTICS : Presents Data Demonstrating Significant Burden of Illness i..
10/17 AKCEA THERAPEUTICS : Presents Data Demonstrating Significant Burden of Illness i..
10/17 IONIS PHARMACEUTICALS : Initiates Clinical Study of IONIS MAPT Rx in Patients wi..
10/16 IONIS PHARMACEUTICALS INC : Featured Company News - Ionis Pharma Commences Phase..
10/16 IONIS PHARMACEUTICALS : begins human trials of Alzheimer's drug
10/13 IONIS PHARMACEUTICALS : Initiates Clinical Study of IONIS-MAPT Rx in Patients wi..
10/12 IONIS PHARMACEUTICALS : Reports Findings in RNase (Dynamic nucleoplasmic and nuc..
10/11 AKCEA THERAPEUTICS : Volanesorsen Receives Promising Innovative Medicine (PIM) S..
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
ISIS PHARMACEUTICALS - 2014
A resistance as obstacle
SELL
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 15
Average target price 54,4 $
Spread / Average Target -15%
EPS Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Inside Director
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
Joseph H. Wender Independent Outside Director
Frederick T. Muto Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, INC.-6.12%7 945
INCYTE CORPORATION14.83%24 254
QUINTILES IMS HOLDINGS INC32.72%21 711
CELLTRION, INC.--.--%20 802
LONZA GROUP59.82%19 730
ALNYLAM PHARMACEUTICALS, INC.213.97%10 783